Postma TJ - Search Results

1

Symptoms and medication management in the end of life phase of high-grade glioma patients.

Koekkoek JA, Dirven L, Sizoo EM, Pasman HR, Heimans JJ, Postma TJ, Deliens L, Grant R, McNamara S, Stockhammer G, Medicus E, Taphoorn MJ, Reijneveld JC. Koekkoek JA, et al. Among authors: postma tj. J Neurooncol. 2014 Dec;120(3):589-95. doi: 10.1007/s11060-014-1591-2. Epub 2014 Aug 24. J Neurooncol. 2014. PMID: 25151506

2

High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.

Vermorken JB, ten Bokkel Huinink WW, Mandjes IA, Postma TJ, Huizing MT, Heimans JJ, Beijnen JH, Bierhorst F, Winograd B, Pinedo HM. Vermorken JB, et al. Among authors: postma tj. Semin Oncol. 1995 Aug;22(4 Suppl 8):16-22. Semin Oncol. 1995. PMID: 7543699 Clinical Trial.

3

Paclitaxel-induced neuropathy.

Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM, Heimans JJ. Postma TJ, et al. Ann Oncol. 1995 May;6(5):489-94. doi: 10.1093/oxfordjournals.annonc.a059220. Ann Oncol. 1995. PMID: 7669713 Free article. Clinical Trial.

4

Long-term effects of vincristine on the peripheral nervous system.

Postma TJ, Benard BA, Huijgens PC, Ossenkoppele GJ, Heimans JJ. Postma TJ, et al. J Neurooncol. 1993 Jan;15(1):23-7. doi: 10.1007/BF01050259. J Neurooncol. 1993. PMID: 8384253

5

Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma.

Postma TJ, van Groeningen CJ, Witjes RJ, Weerts JG, Kralendonk JH, Heimans JJ. Postma TJ, et al. J Neurooncol. 1998 May;38(1):69-75. doi: 10.1023/a:1005909318270. J Neurooncol. 1998. PMID: 9540059

6

Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy.

Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK. Postma TJ, et al. Ann Oncol. 1998 Jul;9(7):739-44. doi: 10.1023/a:1008344507482. Ann Oncol. 1998. PMID: 9739440 Free article.

7

Thallium-201 SPECT as response parameter for PCV chemotherapy in recurrent glioma.

Roesdi MF, Postma TJ, Hoekstra OS, van Groeningen CJ, Wolbers JG, Heimans JJ. Roesdi MF, et al. Among authors: postma tj. J Neurooncol. 1998 Dec;40(3):251-5. doi: 10.1023/a:1006090807678. J Neurooncol. 1998. PMID: 10066098

8

In vitro protection from cisplatin-induced neurotoxicity by amifostine and its metabolite WR1065.

Verstappen CC, Geldof AA, Postma TJ, Heimans JJ. Verstappen CC, et al. Among authors: postma tj. J Neurooncol. 1999 Aug;44(1):1-5. doi: 10.1023/a:1006241622639. J Neurooncol. 1999. PMID: 10582662

9

Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer.

Postma TJ, Hoekman K, van Riel JM, Heimans JJ, Vermorken JB. Postma TJ, et al. J Neurooncol. 1999;45(3):241-6. doi: 10.1023/a:1006343818656. J Neurooncol. 1999. PMID: 10845395 Clinical Trial.

10

A phase II study of paclitaxel in chemonaïve patients with recurrent high-grade glioma.

Postma TJ, Heimans JJ, Luykx SA, van Groeningen CJ, Beenen LF, Hoekstra OS, Taphoorn MJ, Zonnenberg BA, Klein M, Vermorken JB. Postma TJ, et al. Ann Oncol. 2000 Apr;11(4):409-13. doi: 10.1023/a:1008376123066. Ann Oncol. 2000. PMID: 10847458 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

98 results

Search Page

Filters